KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Capital Expenditures (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Capital Expenditures for 8 consecutive years, with $348000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 82.56% to $348000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 33.82% year-over-year, with the annual reading at $4.8 million for FY2025, 33.82% down from the prior year.
  • Capital Expenditures hit $348000.0 in Q4 2025 for Vir Biotechnology, up from $317000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $20.6 million in Q2 2022 to a low of $317000.0 in Q3 2025.
  • Historically, Capital Expenditures has averaged $6.2 million across 5 years, with a median of $2.7 million in 2024.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 6149.54% in 2021 and later crashed 92.96% in 2024.
  • Year by year, Capital Expenditures stood at $13.1 million in 2021, then dropped by 3.77% to $12.6 million in 2022, then tumbled by 87.79% to $1.5 million in 2023, then increased by 29.97% to $2.0 million in 2024, then crashed by 82.56% to $348000.0 in 2025.
  • Business Quant data shows Capital Expenditures for VIR at $348000.0 in Q4 2025, $317000.0 in Q3 2025, and $2.5 million in Q2 2025.